Literature DB >> 16691408

Infections and vaccinations preceding childhood Guillain-Barré syndrome: a prospective study.

Joachim Schessl1, Birgit Luther, Janbernd Kirschner, Gottfried Mauff, Rudolf Korinthenberg.   

Abstract

INTRODUCTION: We performed a prospective, multicentre study in children with Guillain-Barré syndrome (GBS), diagnosed according to international criteria, to investigate the frequency and aetiology of antecedent diseases. All infections and vaccinations occurring within a 6-week period prior to the onset of GBS were documented.
MATERIALS AND METHODS: Stool cultures, standardised serological investigations and PCR analyses for 24 different infective agents were performed. Serological findings were regarded as significant if specific immunoglobulin (Ig)M or IgA antibodies were detected, if the IgM enzyme immunoassay or immunfluorescence assay findings were confirmed by immunoblot, if complement fixation test titres rose fourfold or if geometric titres were more than threefold higher than in uninfected control persons. Ninety-five children with GBS were included in the study over a 40-month period. Preceding events were reported in 82%.
RESULTS: Microbiological studies carried out on 84 patients resulted in a probable diagnosis in 46 (55%). Coxsackieviruses (15%), Chlamydia pneumoniae (8%), cytomegalovirus (7%) and Mycoplasma pneumoniae (7%) were the most frequently involved agents. Serological evidence of a Campylobacter jejuni infection was found in six patients (7%). Eight children had been vaccinated during the 6 weeks preceding the onset of GBS; in six of these children concomitant infectious diseases were reported, and in one child the time between vaccination and GBS was extremely short.
CONCLUSION: We conclude that, in contrast to adults, Campylobacter spp. does not seem to play a major role in childhood GBS in German-speaking countries. The aetiology of antecedent diseases is distributed over a wide spectrum of paediatric infectious diseases. Most of the children who had been vaccinated showed concomitant infectious diseases, thus obscuring the causative role for GBS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16691408     DOI: 10.1007/s00431-006-0140-1

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  39 in total

Review 1.  Assessment of current diagnostic criteria for Guillain-Barré syndrome.

Authors:  A K Asbury; D R Cornblath
Journal:  Ann Neurol       Date:  1990       Impact factor: 10.422

2.  Cluster of childhood Guillain-Barré cases after an oral poliovaccine campaign.

Authors:  M Uhari; H Rantala; M Niemelä
Journal:  Lancet       Date:  1989-08-19       Impact factor: 79.321

3.  Acquisition of cytomegalovirus infection from birth to 10 years: a longitudinal serologic study.

Authors:  M D Yow; N H White; L H Taber; A L Frank; W C Gruber; R A May; H J Norton
Journal:  J Pediatr       Date:  1987-01       Impact factor: 4.406

4.  Campylobacter 0:41 isolation in Guillain-Barré syndrome.

Authors:  E A Goddard; A J Lastovica; A C Argent
Journal:  Arch Dis Child       Date:  1997-06       Impact factor: 3.791

5.  Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barré syndrome.

Authors:  C W Ang; B C Jacobs; A H Brandenburg; J D Laman; F G van der Meché; A D Osterhaus; P A van Doorn
Journal:  Neurology       Date:  2000-04-11       Impact factor: 9.910

6.  Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study.

Authors:  R Korinthenberg; J S Mönting
Journal:  Arch Dis Child       Date:  1996-04       Impact factor: 3.791

7.  Distribution of serotypes and biotypes of thermophilic campylobacters in the Federal Republic of Germany: a comparison with other countries.

Authors:  W Bär; G Fricke; H Goossens
Journal:  Zentralbl Bakteriol       Date:  1989-05

8.  Human serum antibody response to Campylobacter jejuni infection as measured in an enzyme-linked immunosorbent assay.

Authors:  M J Blaser; D J Duncan
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

9.  Long-term epidemiology of infections with Mycoplasma pneumoniae.

Authors:  H M Foy; G E Kenny; M K Cooney; I D Allan
Journal:  J Infect Dis       Date:  1979-06       Impact factor: 5.226

10.  The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.

Authors:  T Lasky; G J Terracciano; L Magder; C L Koski; M Ballesteros; D Nash; S Clark; P Haber; P D Stolley; L B Schonberger; R T Chen
Journal:  N Engl J Med       Date:  1998-12-17       Impact factor: 91.245

View more
  6 in total

Review 1.  Guillain-Barré syndrome--a classical autoimmune disease triggered by infection or vaccination.

Authors:  Eitan Israeli; Nancy Agmon-Levin; Miri Blank; Joab Chapman; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

2.  Prospective study on anti-ganglioside antibodies in childhood Guillain-Barré syndrome.

Authors:  J Schessl; M Koga; K Funakoshi; J Kirschner; W Muellges; A Weishaupt; R Gold; R Korinthenberg
Journal:  Arch Dis Child       Date:  2006-08-18       Impact factor: 3.791

3.  Acupuncture Treatment of Guillain-Barré Syndrome After Using Immune Checkpoint Inhibitors: A Case Report.

Authors:  Jialing Li; Danghan Xu; Yingyu Liu; Yang Cao; Jun He; Muxi Liao
Journal:  Front Neurol       Date:  2022-06-02       Impact factor: 4.086

4.  Weakness and the inability to ambulate in a 14-month-old female: a case report and concise review of guillain-barre syndrome.

Authors:  Scott A Bloch; Mahsa Akhavan; Jahn Avarello
Journal:  Case Rep Emerg Med       Date:  2013-01-30

5.  A New Observation of an Atypical and Severe Variant of the Guillain-Barre Syndrome in a Child: Remaining Challenges for Diagnosis, Nosologic Classification, and Therapeutic Course.

Authors:  Linda Pons; Véronique Manel; Dorothée Ville; Etienne Javouhey; Fabienne Bordet
Journal:  Child Neurol Open       Date:  2015-10-26

Review 6.  Post-infectious neurological disorders.

Authors:  Kyle M Blackburn; Cynthia Wang
Journal:  Ther Adv Neurol Disord       Date:  2020-08-30       Impact factor: 6.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.